About Us

Our Story

As a privately held sleep solutions and connected health innovator, Somnera develops and delivers alternative options for sleep apnea therapy. The Somnera® System received initial FDA clearance in 2018 and was approved as a full-featured, FDA-cleared product in June 2020. The system is now available to purchase to treat your Obstructive Sleep Apnea (OSA).

The Somnera System is a small, lightweight, and easy to use sleep apnea treatment device, ushering a new era of sleep for OSA patients as an alternative to CPAP therapy. The small, elegant, and easy to use design is complemented by new features fashioned to engage and delight our customers. Somnera’s technology is cloud-connected for a data analytics approach towards a better night’s sleep. Patients are able to engage with virtual sleep coaches to better understand and support their sleep journey.

Somnera holds a broad and expanding portfolio of issued US patents, has completed two successful clinical studies, and is now launching the Somnera System in the United States. Somnera’s dedicated and experienced management team is poised to capture share in the $35B available market for better OSA therapies and provide outstanding return to its shareholders by introducing the best alternative solution to sleep apnea therapy in the United States. Learn more about the leadership team, board members, and advisors leading the fight against sleep apnea at Somnera. Let’s reclaim the night together!

Our Leadership

John Cox

President & CEO

Mary Lou Mooney

Vice President – Clinical, Regulatory & Quality Affairs

Tracy Maahs

Vice President – Operations & Engineering

Ed McCarthy

Director of Business Development

Our Board & Advisors

Otto To

Board Member

Matthew Weil

Board Member

George Wallace

Co-Founder & Advisor
(Board Observer)

Andrew Cragg, MD

Co-Founder & Advisor
(Board Observer)